Clinical Study Report (Abbreviated) — GLPI103-102 (MAD / early efficacy)
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. An abbreviated clinical study report for the multiple-ascending-dose (MAD) study with early efficacy signals.
Why it exists. After single doses, repeated dosing tests steady-state safety and PK and looks for early pharmacodynamic effect (e.g., glucose, weight). It informs the dose range taken into Phase 2.
How it is produced here. This is an early-phase (first-in-human / Phase 2) report written as a short narrative. It is a portfolio stand-in, kept deliberately consistent with the rest of the program (the doses, the pharmacology, the safety story all line up).
Format & governing standard. ICH E3 (abbreviated report — early-phase)
Clinical Study Report (Abbreviated) — GLPI103-102 (MAD / early efficacy)
| Field | Value |
|---|---|
| Document ID | CSR-102 |
| Version | 3.0 |
| Sponsor | Virtual Biopharma Inc. |
| Study No. | GLPI103-102 |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH E3 (abbreviated report — early-phase) |
| Confidentiality | Confidential — portfolio use |
[MOCK — deep-knowledge assumption]Illustrative; consistent with IB-001 and REF-002.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Clinical | Initial abbreviated CSR |
| 2.0 | 2026-06-30 | Clinical | Expanded to fuller ICH E3 structure (ethics, design, disposition, PK, efficacy, safety) |
| 3.0 | 2026-07-05 | Clinical | Submission-grade — added disposition, steady-state PK, and early-efficacy tables and a limitations section |
1. Synopsis
| Item | Description |
|---|---|
| Design | Phase 1b, randomized, double-blind, placebo-controlled, Multiple Ascending Dose (MAD) |
| Population | Overweight/obese adults with T2DM or prediabetes (patients, not healthy volunteers) |
| N | 40 (4 dose cohorts × 10; 8 active : 2 placebo) |
| Duration | Up to 12 weeks |
| Objectives | Safety/tolerability, multiple-dose PK; early efficacy (HbA1c, weight) and cardiometabolic biomarkers |
2. Ethics and Study Administration
Conducted per the Declaration of Helsinki, ICH E6(R3) GCP, and applicable regulations, with IRB/IEC approval and written informed consent. Cumulative safety was reviewed before each dose-cohort escalation [MOCK].
3. Rationale for Patient Population
Because the study evaluates multiple-dose early efficacy (HbA1c, weight), the population is patients with elevated baseline HbA1c — a healthy-volunteer MAD could not show glycemic reduction. This corrects a common design inconsistency and aligns the study with its readouts (REF-002 §3).
4. Investigational Plan
- Design: double-blind, placebo-controlled, parallel dose cohorts with repeat dosing and titration to manage gastrointestinal tolerability.
- Dose cohorts
[MOCK]: four ascending multiple-dose levels, each 10 subjects (8 active : 2 placebo), bracketing the projected therapeutic exposure. - Eligibility: adults with T2DM or prediabetes, BMI ≥27 kg/m², HbA1c in a defined range; standard GLP-1-class exclusions (MTC/MEN 2, pancreatitis history).
- Endpoints: safety/tolerability; steady-state PK; HbA1c and body-weight change; cardiometabolic biomarkers (NT-proBNP, hsCRP, HOMA-IR).
5. Study Subjects and Disposition [MOCK]
| Cohort (dose) | Active : PBO | Completed 12 wk | Discontinued |
|---|---|---|---|
| 1 (lowest) | 8 : 2 | 10 | 0 |
| 2 | 8 : 2 | 9 | 1 |
| 3 | 8 : 2 | 9 | 1 |
| 4 (highest) | 8 : 2 | 8 | 2 |
| Total | 32 : 8 | 36 | 4 |
The majority completed 12 weeks; the infrequent early discontinuations were for gastrointestinal tolerability at the higher cohorts. Baseline characteristics reflected an overweight/obese T2DM/prediabetes population (mean BMI ~31 kg/m²; HbA1c ~7.6%).
6. Pharmacokinetic Results [MOCK]
| PK parameter | Finding |
|---|---|
| Accumulation | modest, predictable (consistent with single-dose t½ ~130 h) |
| Time to steady state | within ~4–5 weeks of repeat dosing |
| Dose-exposure | exposure increased across the tested cohorts (approximately dose-proportional) |
| Immunogenicity | low-titre, non-neutralizing ADA; no PK impact |
Repeat dosing produced predictable accumulation reaching steady state within the dosing schedule, supporting the once-weekly (IV) / once-daily (oral) regimens (CLINPHARM-002).
7. Efficacy / Biomarker Results [MOCK]
| Endpoint (12 wk, top dose vs placebo) | Result |
|---|---|
| HbA1c CFB | ≈ −0.8% |
| Body-weight CFB | ≈ −3 kg |
| NT-proBNP / hsCRP | favourable change |
Effects were dose-dependent and supported the APJ-mediated mechanistic hypothesis and the Phase 2 dose range.
8. Safety Results [MOCK]
Dose-dependent, mostly mild–moderate gastrointestinal AEs managed by titration; no SAEs; no clinically significant laboratory, ECG, or vital-sign trends.
9. Discussion and Conclusions
Multiple doses were tolerable with titration and produced dose-dependent glycemic, weight, and cardiometabolic-biomarker effects, supporting Phase 2 dose-finding (GLPI103-201) and the doses carried into Phase 3.
10. Limitations
Small, short (12-week) early-phase study; efficacy signals are exploratory [MOCK] and were confirmed in the dose-finding (CSR-201) and pivotal (CSR-301) studies. PK conclusions are integrated in the clinical-pharmacology summary (M2.7.2; CLINPHARM-002).
Comments (0)
No comments yet. Be the first to say something!